Nicollet Mall

Scholar Rock Announces Pricing of Upsized Public Offering of Common Stock

Retrieved on:

Thursday, October 12, 2023

Biotechnology, Finance, Health, Professional Services, Pharmaceutical, Telephone, Form S-3, Attention, Prospectus, Gongshi, Form, Broadridge Financial Solutions, Nicollet Mall, Security (finance), Sale

Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the pricing of an upsized underwritten public offering of 12,408,760 shares of its common stock at a public offering price of $6.85 per share.

Key Points:

Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the pricing of an upsized underwritten public offering of 12,408,760 shares of its common stock at a public offering price of $6.85 per share.
The aggregate gross proceeds to Scholar Rock from this offering are expected to be approximately $85.0 million, before deducting underwriting discounts and commissions and other offering expenses.
In addition, Scholar Rock has granted the underwriters a 30-day option to purchase up to an additional 1,861,314 shares of common stock at the public offering price, less the underwriting discounts and commissions.
The securities described above are being offered by Scholar Rock pursuant to a shelf registration statement on Form S-3 (No.

Zip Annual User Conference to Feature Speakers from Discover Financial, Figma, Kearney, Northwestern Mutual, OpenAI, Snowflake, Two Sigma, UC Irvine Health and WestCap

Retrieved on:

Friday, October 6, 2023

Zip , the world’s only intake-to-pay platform, today announced the speaker lineup for its inaugural annual user conference, Zip Forward .

Key Points:

Zip , the world’s only intake-to-pay platform, today announced the speaker lineup for its inaugural annual user conference, Zip Forward .
The conference — which will take place on November 8, 2023, in the heart of San Francisco’s Financial District at The Conservatory at One Sansome — features distinguished guest speakers with unique backgrounds and deep expertise in their respective fields.
Highlights include a keynote from Zip co-founders Rujul Zaparde and Lu Cheng on their founding story and sessions with executives from Discover Financial, Figma, Kearney, Northwestern Mutual, OpenAI, Snowflake, Two Sigma, UC Irvine Health and WestCap.
“Zip is the global standard for intake-to-pay, helping businesses procure with the fastest process, least risk and at the lowest cost.

ALX Oncology Announces Proposed Public Offering

Retrieved on:

Wednesday, October 4, 2023

Attention, CD47, The Women on the 6th Floor, Capital market, Telephone, Sale, Prospectus, SAN, Security (finance), Nicollet Mall

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.

Key Points:

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.
All shares of common stock and pre-funded warrants in this offering will be sold by ALX Oncology.
The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ALX Oncology intends to use the net proceeds from the offering to fund ongoing development of evorpacept, including clinical trials targeting market expansion, and for working capital and general corporate purposes.

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on:

Monday, October 2, 2023

Exercise, Attention, Floor, SVB Securities, The 8th Floor, Telephone, Roivant Sciences, Sale, Prospectus, State Street, Wells Fargo, Form, Madison Avenue, Nicollet Mall, Guggenheim Partners, Security (finance)

This includes the exercise in full by the underwriters of their option to purchase up to 1,105,500 additional shares of common stock.

Key Points:

This includes the exercise in full by the underwriters of their option to purchase up to 1,105,500 additional shares of common stock.
Concurrent with the public offering, Immunovant sold 4,473,684 shares of common stock to Roivant Sciences, Ltd. at a price of $38.00 per share in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, or the Securities Act.
Leerink Partners, Piper Sandler, Guggenheim Securities and Wells Fargo Securities acted as joint bookrunning managers for the public offering.
The shares in the public offering were offered by Immunovant pursuant to a Registration Statement on Form S-3 previously filed and declared effective by the SEC.

Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering

Retrieved on:

Friday, September 29, 2023

The gross proceeds to Madrigal from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $500 million.

Key Points:

The gross proceeds to Madrigal from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $500 million.
Madrigal has granted the underwriters of the offering a 30-day option to purchase up to an additional 494,429 shares of common stock from the company at the public offering price, less underwriting discounts and commissions.
Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Evercore ISI and Piper Sandler are acting as joint bookrunning managers of the offering.
The offering is expected to close on October 3, 2023, subject to the satisfaction of customary closing conditions.

Madrigal Pharmaceuticals Announces Proposed Public Offering

Retrieved on:

Thursday, September 28, 2023

Madrigal also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.

Key Points:

Madrigal also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.
All of the shares in the proposed offering are to be sold by Madrigal.
Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Evercore ISI and Piper Sandler are acting as joint bookrunning managers of the proposed offering.
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Immunovant Announces Pricing of $450 Million Common Stock Financing

Retrieved on:

Thursday, September 28, 2023

Attention, Floor, SVB Securities, The 8th Floor, Telephone, Roivant Sciences, Sale, Prospectus, State Street, Wells Fargo, Form, Madison Avenue, Nicollet Mall, Guggenheim Partners, Security (finance)

All of the shares are to be sold by Immunovant.

Key Points:

All of the shares are to be sold by Immunovant.
Immunovant offered 7,370,000 shares of its common stock in the public offering, at an offering price of $38.00 per share.
In addition, Immunovant has granted the underwriters for the public offering a 30-day option to purchase up to an additional 1,105,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.
Leerink Partners, Piper Sandler, Guggenheim Securities and Wells Fargo Securities are acting as joint bookrunning managers for the public offering.

Immunovant Announces Proposed Offering of $300 Million of Common Stock

Retrieved on:

Tuesday, September 26, 2023

Attention, Floor, SVB Securities, The 8th Floor, Telephone, Roivant Sciences, Sale, Prospectus, State Street, Wells Fargo, Form, Madison Avenue, Nicollet Mall, Guggenheim Partners, Security (finance)

Immunovant intends to offer and sell $130,000,000 of shares of its common stock in an underwritten public offering.

Key Points:

Immunovant intends to offer and sell $130,000,000 of shares of its common stock in an underwritten public offering.
In addition, Immunovant intends to grant the underwriters for the offering a 30-day option to purchase up to an additional $19,500,000 of shares of its common stock offered at the public offering price.
Concurrent with the proposed public offering, Immunovant intends to sell $170,000,000 of shares of its common stock to Roivant Sciences Ltd. in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, subject to consummation of the proposed public offering and other customary conditions.
The proposed public offering and concurrent private placement are subject to market and other conditions, and there can be no assurance as to whether or when the proposed public offering and concurrent private placement may be completed, or the actual size or terms of the proposed public offering and concurrent private placement.

CymaBay Announces Closing of Upsized $258.7 Million Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on:

Thursday, September 14, 2023

Exercise, Attention, The Women on the 6th Floor, Capital market, Telephone, Sale, Prospectus, Liver, Conditional sentence, Nicollet Mall, Security (finance), Syndicate, Therapy

CymaBay sold 14,521,307 shares of common stock in the offering, including 1,970,227 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $17.13 per share.

Key Points:

CymaBay sold 14,521,307 shares of common stock in the offering, including 1,970,227 shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $17.13 per share.
In addition, CymaBay sold, in lieu of common stock to certain investors, pre-funded warrants to purchase 583,771 shares of common stock in the offering at a public offering price of $17.1299 per underlying share.
The gross offering proceeds to CymaBay from this offering were approximately $258.7 million, before deducting the underwriting discount and other estimated offering expenses, and excluding the exercise of any pre-funded warrants.
All shares of common stock and pre-funded warrants were offered by CymaBay.

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Retrieved on:

Wednesday, September 13, 2023

Morgan Stanley, Attention, SVB Securities, Varick Street, Therapy, Telephone, Research, Sale, Prospectus, State Street, SAN, Security (finance), Nicollet Mall, 2nd Floor, Broadridge Financial Solutions

All of the shares to be sold in the offering are to be sold by Crinetics.

Key Points:

All of the shares to be sold in the offering are to be sold by Crinetics.
The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $350.0 million.
In addition, Crinetics has granted the underwriters a 30-day option to purchase up to an additional 1,716,247 shares of common stock.
The offering is expected to close on or about September 15, 2023, subject to the satisfaction of customary closing conditions.